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Introduction:  Asthma is an inflammatory condition of the lungs that can have 
significant impacts on a patient’s quality of life. Asthma attacks can be very 
uncomfortable and even deadly in some cases. The objective of this study is to evaluate 
the treatment of asthma in the state of Mississippi and to describe the disparities between 
demographics to help healthcare providers identify patients who might be at risk for poor 
treatment and help those patients receive quality healthcare. Methods: The data was 
retrospectively collected from January to December 2014 Mississippi Centers for 
Medicare and Medicaid Services claims data. This study is a retrospective, longitudinal, 
analytical, non-experimental design to describe the quality of asthma treatment in the 
state of Mississippi. The study uses two measures from the Healthcare Effectiveness Data 
and Information Set (HEDIS), the Asthma Medication Ratio (AMR) and Medication 
Management for People With Asthma (MMA). Results: The results are split into two 
main categories, AMR and MMA. The AMR section is then divided into categories for 
age, race, and sex. The MMA measure is further divided into Proportion of Days 
Covered>50% (PDC50) and Proportion of Days Covered>75% (PDC75) for the 
categories of age, race, and sex. The results showed significant differences among 
demographics for each measure except for MMA PDC75 by Sex. Discussion: These 
differences could be due to medication adherence issues, the misclassification of 
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Description of the Problem 
 
  According to the Center for Disease Control and Prevention, as of 2017, 
there were over 25 million Americans living with asthma, or, roughly, 8% of the 
population. There were also over 3,500 deaths, in 2017, with asthma as the main cause. 
The CDC also states that there are 187,772 people in Mississippi living with asthma, or 
8.3% of the state population. Mississippi had 47 deaths attributable to asthma in 2017 
(Asthma State Data, 2019). Though the state average is close to the national average for 
citizens living with asthma, the mean of Mississippians, especially children, living with 
uncontrolled asthma is significantly higher than the national average, with 53.1% of 
children in Mississippi vs 38.4% of children nationally (AsthmaStats 2014). According to 
the Asthma and Allergy Foundation of America, between 2008 and 2013, asthma 
accounted for over $50 billion in medical costs alone, not including the other economic 
costs associated with it. This averages over $6 billion per year. (AAFA) 
 
Causes of Asthma 
Asthma is a chronic lung disease that causes the airways to be inflamed and 
narrow, making it difficult to breathe. During an exacerbation, symptoms worsen, making 
it even harder to breathe. Symptoms of an asthma exacerbation include; wheezing, 
shortness of breath, tachypnea (rapid breathing), and coughing. If severe enough, the 
asthma exacerbation can be life threatening with symptoms such as cyanosis (a condition 
where the lips and fingertips turn blue from lack of oxygen), flaring of the nostrils, very 
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fast movement of the stomach or ribs with breathing, incomplete exhalation, or, in 
infants, unresponsiveness to parents. (AAFA)  
 Asthma exacerbations can be triggered by a several different factors, including 
physical activity, allergens, or occupational factors such as fumes or dust. When an 
irritant encounters a patient with asthma’s airways, the airways become inflamed and 
constricted, causing the symptoms seen in asthma exacerbations. (AAAI) 
 
Treatment of Asthma 
 The two main types of medication used to treat asthma are controller and reliever 
medications. Controller medications are taken prophylactically every day to prevent 
asthma exacerbations and control the daily symptoms of asthma. Types of controller 
medications include: inhaled corticosteroids, inhaled corticosteroid combinations, long 
acting beta-2 agonists, leukotriene modifiers, mast cell stabilizers, methylxanthines, and 
immune modulators. Reliever medications are typically short-acting, inhaled beta-2 
agonists. The treatment of asthma is dependent on whether it is classified as intermittent 
or persistent. The differences in these two classes can be seen in Appendix B. Intermittent 
asthma does not require a controller medication while persistent does and could require 
multiple (Asthma Quick Care Reference, 2012). 
 
 
Quality Control Measures 
  
 Quality of care, as defined by the Institute of Medicine, is “the degree to which 
health services for individuals and populations increase the likelihood of desired health 
outcomes and are consistent with current professional knowledge” (Lohr, 1990). As 
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different options for health insurance began to arise in the 20th century, so too did the 
need for a way to measure the quality of care received by patients. The need partly arose 
from economic reasons and partly from a wellbeing of the patient side. The patients 
needed to know that they were going to receive the best healthcare possible and the 
insurance company wanted to ensure that their money was being spent efficiently on 
capable doctors and hospitals (McIntyre et al, 2001). The National Committee on Quality 
Assurance (NCQA) created the Healthcare Effectiveness and Data Information Set 
(HEDIS) as a quality control measure to be used by consumers and insurers alike. HEDIS 
is composed of six domains of care composed of ninety quality control measures. 
According to the NCQA website, “191 million people are enrolled in plans that report 
HEDIS results,” which is over half the United States population according to recent 
census data (HEDIS) (US Census Bureau, 2011). 
This study will be using the HEDIS Asthma Medication Ratio (AMR) and 
Medication Management for People with Asthma (MMA) quality control measures. 
AMR is the ratio of controller medications to total asthma medications. MMA measures 
the mean of people who remain on a controller medication for at least 50% of their 
treatment period and the mean of people who remain on a controller medication for at 
least 75% of their treatment period. 
 
 
Medicare and Medicaid 
  
 In 1965, Congress added amendments XVIII and XIX to the Social Security Act, 
establishing Medicare and Medicaid, respectively. Medicare gives coverage to all citizens 
over the age of 65, regardless of past medical history. Medicaid is meant to give coverage 
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to lower income citizens; however, it is made to be state run but was not made mandatory 
for each state to have a program. Both programs are administered by the Centers for 
Medicare and Medicaid Services (CMS). 
 There have been several changes to Medicare since 1965. Currently it is divided 
into 4 parts: Part A, Part B, Part C, and Part D. Medicare provides coverage to anybody 
over the age of 65, people with end stage renal-disease or amyotrophic lateral sclerosis, 
and some disabled people under the age of 65. As well as the previously mentioned 
health status’, in order to be eligible for Medicare a person must also be a citizen and 
he/she or their spouse must have worked in a Medicare eligible job for at least ten years. 
Part A, also known as Hospital Insurance (HI), is paid for through the HI Trust Fund 
which is funded through payroll tax and also partly through a deductible paid by the 
patient. It covers in-patient hospital visits, care at a skilled nursing facility, home health, 
and hospice care. There is also automatic enrollment for Part A. Part B, also known as 
Supplementary Medical Insurance (SMI), is paid for through the SMI Trust Fund, which 
is funded through patient premiums and through revenues from the federal government. 
Part B covers most outpatient visits and some drugs, such as those that cannot be 
administered by the patient, but it does not cover hearing, vision, dental, or most 
prescription drugs. To be eligible for Part B, the patient must also be enrolled in Part A 
however, enrollment in Part B is voluntary and not automatic. Part C, also known as 
Managed Care, is a plan available to those enrolled in Part A and Part B. Part C is a 
program where the patient is enrolled in a private insurance company but Medicare is 
paying a predetermined amount to the company to offset the cost. These plans are 
required to cover the same elements as Part A and Part B but can cover more. Many Part 
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C plans also offer coverage for prescription drugs, vision, dental, and hearing. 
Beneficiaries of these plans pay the Part B premium as well as an additional premium for 
any additional coverage. Medicare Part D is available to those enrolled in Part A and Part 
B. Part D is funded through the SMI Trust Fund and covers prescription drugs. 
Beneficiaries are allowed to choose their own prescription drug plan. These plans must 
include a Medication Therapy Management program to help increase patient 
understanding, adherence, and decrease adverse events. 
 Whereas Medicare is almost exclusively for people over the age of 65, with some 
exceptions, Medicaid is for people of any age who do not have the means to afford 
healthcare on their own. It is funded by both the state and federal governments, with the 
federal government contributing an amount proportional to the state’s average income 
level. Medicaid is also administered by the individual state, with some national 
guidelines. There are three groups covered under Medicaid: the Mandated Categorically 
Needy, Optionally Categorically Needy, and Medically Needy. The Mandated 
Categorically Needy includes children under the age of 19 whose family’s income is less 
than 138% of the Federal Poverty Line (FPL), pregnant women whose income is less 
than 133% of the FPL, parents who receive welfare, and people with disabilities who 
receive a Supplemental Security Income below 79% of the FPL. The Optionally 
Categorically Needy category is determined by the states but must include the same 
benefits and coverage as the Mandated category. The Medically Needy category includes 
individuals who make above the FPL thresholds to fit into another category but spend so 







This study will help to identify specific at-risk populations for poor treatment of 
asthma in the state of Mississippi. This will help healthcare providers, such as primary 
care providers, pharmacists, and nurses, to be more vigilant in identifying and assisting in 
suboptimal treatment. In preparation for this study, a literature review was conducted, 
and it was found that a similar study was conducted in one aspect by the Mississippi Drug 
Utilization Review Board (Asthma Overview, 2019); however, that study was much 





The objectives of this study are: 
1. To evaluate the performance on HEDIS Medication Management for people with 
Asthma (MMA) and Asthma Medication Ratio (AMR) among patients with 
persistent asthma using claims data from CMS Medicaid. 
2. To describe the demographic variations of MMA and AMR for patients enrolled 
in Mississippi Medicaid with persistent asthma. 








The study was conducted using a retrospective, longitudinal, analytical, non-
experimental design to describe the quality of asthma treatment in the state of Mississippi 
using Mississippi Centers for Medicare and Medicaid Services claims data. This study is 
approved by the University of Mississippi Institutional Review Board, the protocol 
number is 19-051. 
 
Sample 
 The sampled data is consistent with the parameters set forth by HEDIS 
AMR and MMA measures. See Appendix A for AMR and MMA measures, respectively. 
The study was conducted using Mississippi Centers for Medicare and Medicaid Services 
claims data for calendar year 2014. Beneficiaries with persistent asthma were identified 
and classified as receiving appropriate treatment or not using the specifications in the 
HEDIS quality measures for asthma treatment. Demographic characteristics of 
beneficiaries were determined from the CMS beneficiary summary files and 
comorbidities were identified using medical claims for the beneficiaries included in the 
study. The AMR set consists of 17,997 patients and the MMA set consists of 14,014 
patients. The difference is that the AMR measure excludes patients who received no 
asthma medications, whether controller or reliever, while the MMA measure only 






Data Collection and Analysis 
 All data collected was retrospective claims data from the Mississippi Centers for 
Medicare and Medicaid Services. Descriptive statistics and logistic regressions will be 
used to compare performance on the HEDIS measures across beneficiary characteristics 
and to identify disparities in the treatment of asthma in Mississippi.  
The AMR is the ratio of controller asthma medications to total asthma 
medications. The ideal ratio is greater than 0.5, where no other medications are needed, 
and the asthma is controlled.  
The MMA measure is quantified by using the Proportion of Days Covered (PDC). 
This is the proportion of days on an asthma controller medication related to the total 
number of days in the treatment period. The first category is PDC50, which is the number 
of persons who were on a controller medication for over 50% of the treatment period. 
The second category is PDC75, which is the number of persons who were on a controller 
medication for over 75% of the treatment period. For this study, the study population was 
assigned numerical values to measure the PDC50 and PDC75. Those with a score of 
PDC<50% or PDC<75% are deemed unfavorable outcomes. Those with a score of 









The AMR measure was composed of 17,997 individuals ranging from 5 years old 
to 64 years old representing six racial categories. Table 1 shows the frequency and mean 
of the overall population with an AMR of less than or greater than or equal to 0.5. 
Approximately 69.01% of the population received an AMR greater than or equal to 0.5. 
As shown in Table 2, the average age was 16 years old with 12 years old being the 
median. Tables 3 shows the frequency and mean for each age group.  
Table 4 shows the analysis of AMR by a function of the age group demographic, 
with the associated Chi-Square Test. Approximately 79.23% of 5-11 year olds, 68.06% of 
12-18 year olds, 43.51% of 19-50 year olds, and 58.48% of 51-64 year olds, had an AMR 
score of 0.5 or greater. The Chi-Square Test gives a p-value of less than 0.0001. This 
means that for the 95% confidence interval, there is a statistically significant difference 
between the groups. 
Table 5 shows the frequency and mean for each racial demographic. Table 6 
shows the analysis of AMR by a function of the race demographic with the associated 
Chi-Square Test. Approximately 66.19% of African Americans, 74.07% of American 
Indians, 88.52% of Asians, 74.49% of Caucasians, 69.52% of Hispanics, and 66.95% of 
the Unknown/Other category, had an AMR score of 0.5 or greater. The Chi-Square Test 
gives a p-value of less than 0.0001. This means that for the 95% confidence interval, 
there is a statistically significant difference between the groups. 
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Table 7 shows the frequency and mean for males and females. Table 8 shows the 
analysis of AMR by a function of sex, with the corresponding Chi-Square Test. 
Approximately 64.89% of females had an AMR score of 0.5 or greater while 72.98% of 
males did. The Chi-Square Test gives a p-value of less than 0.0001. This means that for 
the 95% confidence interval, there is a statistically significant difference between the 
groups. 
The MMA measure was composed of 14,014 individuals broken down into the 
same demographic categories as the AMR measure. The data is divided into two sections, 
PDC50 and PDC75, and further divided into race, sex, and age group. The overall PDC50 
and PDC75 data is shown in Tables 9 and 10, respectively. For PDC50, approximately 
41.07% of individuals received a score of 1. For PDC75, approximately 18.10% of 
individuals received a score of 1. 
 Table 11 shows the frequency and mean of the age group categories for the 
MMA measure. Table 12 shows the analysis of PDC50 by age group, with the   
associated Chi-Square Test. Approximately 41.27% of 5-11 year olds, 37.97% of 12-18 
year olds, 43.91% of 19-50 year olds, and 53.89% of 51-64 year olds, received a score   
of 1. The Chi-Square Test gives a p-value of less than 0.0001. This means that for the 
95% confidence interval, there is a statistically significant difference between the   
groups. 
In Table 13 the analysis of PDC75 is shown by age group, with the associated 
Chi-Square Test. Approximately 17.64% of 5-11 year olds, 15.91% of 12-18 year olds, 
21.79% of 19-50 year olds, and 31.11% of 51-64 year olds, received a score of 1. The 
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Chi-Square Test gives a p-value of less than 0.0001. This means that for the 95% 
confidence interval, there is a statistically significant difference between the groups. 
Table 14 shows the frequency and mean of the racial group categories for the 
MMA measure. In Table 15, the analysis of PDC50 is shown by race, with the 
corresponding Chi-Square Test. Approximately 36.39% of African Americans, 37.50% 
of American Indians, 43.40% of Asians, 50.96% of Caucasians, 42.08% of Hispanics, 
and 50.32% of Unknown/Others, received a score of 1. The Chi-Square Test gives a p-
value of less than 0.0001. This means that for the 95% confidence interval, there is a 
statistically significant difference between the groups. 
Table 16 shows the analysis of PDC75 by race, with the corresponding Chi-
Square Test. Approximately 14.17% of African Americans, 12.50% of American Indians, 
28.30% of Asians, 25.89% of Caucasians, 18.33% of Hispanics, and 28.46% of 
Unknown/Others, received a score of 1. The Chi-Square Test gives a p-value of less than 
0.0001. This means that for the 95% confidence interval, there is a statistically significant 
difference between the groups. 
Table 17 shows the frequency and mean of the males and females for the MMA 
measure In Table 18, the analysis of PDC50 is shown by sex, with the corresponding 
Chi-Square Test. Approximately 40.11% of females and 41.90% of males received a 
score of 1. The Chi-Square Test gives a p-value of 0.0312. This means that for the 95% 
confidence interval, there is a statistically significant difference between the groups. 
Table 19 shows the analysis of PDC75 by sex, with the corresponding Chi-Square 
Test. Approximately 17.82% of females and 18.33% of males received a score of 1. The 
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Chi-Square Test gives a p-value of 0.4377. This means that for the 95% confidence 


























Table 1: Overall AMR 
AMR Frequency (n) Mean (%) 
< 0.5 5578 30.99 
> 0.5 12419 69.01 
 
Table 2: AMR and Age Statistics 
Variable Mean Median Minimum Maximum Standard 
Deviation 
AMR 0.69 1.00 0 1.00 0.46 
Age (years) 16.43 12.00 5.00 64.00 13.67 
 
Table 3: Age Frequency for AMR Ratio 
Age Group 
(years) 
Frequency (n) Mean (%) 
05-11 8,976 49.87 
12-18 5,429 30.17 
19-50 2,606 14.48 
















< 0.5 > 0.5 Total p-value 
05-11 1864 (20.77) 7112 (79.23) 8,976  
 
< 0.0001 
12-18 1734 (31.94) 3695 (68.06) 5,429 
19-50 1472 (56.49) 1134 (43.51) 2,606 
51-64 508 (51.52) 478 (48.48) 986 




Table 5: Race Frequency for AMR Ratio 
Race 
 







Asian 61 0.34 
Caucasian 5728 31.83 
Hispanic 269 1.49 










Table 6: AMR Ratio by Race 
Race AMR Ratio 
Frequency 
Row Mean 
< 0.5 > 0.5 Total p-value 
African 
American 







American Indian 7 (25.93) 20 (74.07) 
 
27 
Asian 7 (11.48) 54 (88.52) 
 
61 
Caucasian 1461 (25.51) 4267 (74.49) 
 
5,728 
Hispanic 82 (30.48) 187 (69.52) 
 
269 
Unknown/Other 275 (33.05) 557 (66.95) 
 
832 




Table 7: Sex Frequency for AMR Ratio 
Sex Frequency (n) Mean (%) 
F 8,837 49.10 
M 9,160 50.90 
 
Table 8: AMR by Sex 
Sex AMR  
Frequency 
Row Mean 
< 0.5 > 0.5 Totals p-value 
Female 3103 (35.11) 5734 (64.89) 8,837  
< 0.0001 Male 2475 (27.02) 6685 (72.98) 9,160 














0 8258 58.93 
1 5756 41.07 
 
Table 10: Overall PDC75 
PDC75 
 
Frequency (n) Mean (%) 
0 11478 81.90 
1 2536 18.10 
 
 
Table 11: MMA Measure Age Group Characteristics 
Age Group 
(years) 







19-50 1487 10.61 






















12-18 2534 (62.03) 1551 (37.97) 4085 
19-50 834 (56.09) 653 (43.91) 1487 
51-64 249 (46.11) 291 (53.89) 540 
Total 8258 (58.93) 5756 (41.07) 14014 
 
Table 13: Age Group by PDC75 















12-18 3435 (84.09) 650 (15.91) 4085 
19-50 1163 (78.21) 324 (21.79) 1487 
51-64 372 (68.89) 168 (31.11) 540 













Table 14: MMA Measure Demographic Characteristics 
Race 
 




American Indian 24 0.17 
Asian 53 0.38 
Caucasian 3789 27.04 
Hispanic 240 1.71 
Unknown/Other 622 4.44 
 













American Indian 15 (62.50) 9 (37.50) 24 
Asian 30 (56.60) 23 (43.40) 53 
Caucasian 1858 (49.04) 1931 (50.96) 3789 
Hispanic 139 (57.92) 101 (42.08) 240 
Unknown/Other 309 (49.68) 313 (50.32) 622 



















American Indian 21 (87.50) 3 (12.50) 24 
Asian 38 (71.70) 15 (28.30) 53 
Caucasian 2808 (74.11) 981 (25.89) 3789 
Hispanic 196 (81.67) 44 (18.33) 240 
Unknown/Other 445 (71.54) 177 (28.46) 622 
Total 11478 (81.90) 2536 (18.10) 14014 
 
Table 17: MMA Measure Sex Characteristics 
Sex 
 
Frequency (n) Mean (%) 
F 6480 46.24 
M 7534 53.76 
 





































Female 5325 (82.18) 1155 (17.82) 6480  
 
0.4377 Male 6153 (81.67) 1381 (18.33) 7534 

























Asthma Medication Ratio Key Findings  
Comparing AMR by age groups, the 05-11 year age group considerably 
outperformed all the other groups. This could be due to adherence issues. If a patient has 
trouble adhering to prescription instructions for a controller medication, which are 
sometimes administered multiple times per day, the patient will need more non-controller 
medications, such as rescue inhalers. This will shift the patient from what could be an 
optimal treatment to a treatment with an unfavorable AMR. That age group is still 
dependent on parents or guardians for their adherence and the parents may follow 
instructions more closely to keep their children healthy. As the patient ages, he/she 
become more independent and though he/she may be able to take his/her medications 
independently, he/she may not to remember to take his/her controller medication. This 
explanation also provides a reason why the 51-64 year age group, outperformed the 19-50 
age group, as an older patient may be more responsible and more likely to take care of 
their health and have better medication adherence (Hadji et al, 2016) 
In AMR by Race, the African American group performed the worst, despite 
having the same insurance and, theoretically, access to the same healthcare providers. 
Similar to how adherence is the reason the 05-11 year age group performed the best, 
adherence could be the reason African Americans performed the worst. These issues 
could be due to cultural barriers, poor health literacy, or poor patient education. 
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For males and females, males performed significantly better than females. This 
could also be due to females being more likely to visit their physician and have their 
medications changed, which would alter the AMR. 
 
Medication Management for People With Asthma Key Findings 
 MMA measures medication adherence by using claims data from pharmacies. 
Looking at the 12-18 year age group by PDC50 and Age Group by PDC75, they 
performed the worst according to the MMA measures with the 05-11 year ago group 
performing the second worst. This could be due to the misclassification of mild asthma as 
persistent asthma skewing the results. After the 12-18 year age group, the PDC50 and 
PDC75 increases as age increases, showing increased adherence. This could be due to 
fewer misclassifications or patients are starting to take their healthcare more seriously 
and getting better about taking their medication.  The average value for PDC50 was 
41.07%, when this is changed to PDC75, the value drops to 18.10%, a relative change of 
-55.97%. This change is similar to what the majority of the demographics experienced. 
This data is also could also be skewed by patients not correctly diagnosed with persistent 
asthma. It also is very telling as to how poorly these controller medications are actually 
taken. Throughout both AMR and MMA measures, every group was statistically 
significantly different with the exception of one, Sex by PDC75. It had a p-value of 
0.4377 meaning that there is not a statistically significant difference in sex. This is most 
likely due to males and females sharing more of the same influences on adherence than 







 The main limitation of this study is that it may not be generalizable to other 
populations because the data was derived from Medicaid claims data. People who are 
enrolled in Medicaid are generally associated with a lower socioeconomic status. People 
of a higher socioeconomic status might have access to more doctors and medications not 
available to Medicaid patients due to factors associated with a lower socioeconomic 
status, such as limitations in number of specialized providers in an area or barriers in 
transportation to providers. A lower socioeconomic status is also generally associated 
with poor health literacy which could affect medication adherence (Wamala et al, 2007). 
People with Medicaid insurance are also limited to 6 prescriptions per month and might 
be less likely to fill a controller prescription as they would a reliever prescription. 
Another limitation is the study uses claims data from the year 2014, which is just one 
year of data. Both measures also include patients who have had four medication 
dispensing events. This allows for the opportunity of misclassification of patients with 
intermittent asthma as patients with persistent asthma. The measures are for patients with 
persistent asthma, but medication dispensing events is not in the criteria for the 
classification of asthma so there is not a guarantee the patients have persistent asthma. 
For AMR, one way the data can become skewed is if a patient goes through many 
different controller medications throughout the year. This would skew the data because 
the ratio would be falsely high due to the amount of controller medications, offsetting the 
non-controller medications. There are multiple ways the MMA data can be skewed. If a 
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person is not correctly diagnosed with persistent asthma, fits the inclusion criteria, is 
started on controller medication, but later reclassified as intermittent asthma, or even no 
asthma at all, and treatment of controller medications is discontinued, those patients will 
still be included in the measure. The MMA data could also be skewed by patients using 
asthma controller medications for seasonal asthma, where they are only adherent to their 
medications for a certain portion of the year. Many people also visit urgent care clinics 
instead of their primary care physician for medical care, this could be a source of error as 
many urgent care offices might not have access to spirometry, a tool needed to accurately 
diagnose and assess asthma. There is also no guarantee the patient took the medication, 
only that the prescription was filled. These two sources of error could account for the 
reason why the PDC50 and PDC75 mean value for 1 was low. 
 
Practical Relevance 
 With certain groups being identified as falling behind other groups in terms of 
performance, healthcare professionals can use this data to try to mediate the disparity. 
Pharmacists, in particular, can be sure to be more vigilant about educating patients about 
the difference in controller and reliever medications and the importance of proper 
technique and adherence. This would improve health outcomes and performance on 
quality control measures. Pharmacists can also be more vigilant about ensuring that 






Ideas for Future Research 
 For future research, it would be advantageous to change the exclusion criteria to 
exclude people whose asthma diagnoses have been downgraded from persistent to 
intermittent. It would also be beneficial to do a similar study showing the variation by 
geographic region. This could help to identify areas of the state that are consistently 
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Asthma Medication Ratio (AMR) 
SUMMARY OF CHANGES TO HEDIS 2017 
• No changes to this measure. 
Description  
The mean of members 5–85 years of age who were identified as having persistent asthma and 
had a ratio of controller medications to total asthma medications of 0.50 or greater during the 
measurement year.  
Note: For Medicaid, report only members 5–64 years of age. For Medicare, report only members 





One prescription of an amount lasting 30 days or less. To calculate dispensing events 
for prescriptions longer than 30 days, divide the days supply by 30 and round down to 
convert. For example, a 100-day prescription is equal to three dispensing events 
(100/30 = 3.33, rounded down to 3). Allocate the dispensing events to the appropriate 
year based on the date on which the prescription is filled. 
Multiple prescriptions for different medications dispensed on the same day are counted 
as separate dispensing events. If multiple prescriptions for the same medication are 
dispensed on the same day, sum the days supply and divide by 30. Use the Drug ID to 
determine if the prescriptions are the same or different. 




When identifying the eligible population, use the definition below to count 
inhaler dispensing events. 
All inhalers (i.e., canisters) of the same medication dispensed on the same day 
count as one dispensing event. Medications with different Drug IDs dispensed 
on the same day are counted as different dispensing events. For example, if a 
member received three canisters of Medication A and two canisters of 
Medication B on the same date, it would count as two dispensing events. 
Allocate the dispensing events to the appropriate year based on the date 
when the prescription was filled. 
 
 28 





Each injection counts as one dispensing event. Multiple dispensed injections of the 
same or different medications count as separate dispensing events. For example, if a 
member received two injections of Medication A and one injection of Medication B on 
the same date, it would count as three dispensing events.  
Allocate the dispensing events to the appropriate year based on the date when the 





When identifying medication units for the numerator, count each individual 
medication, defined as an amount lasting 30 days or less, as one medication 
unit. One medication unit equals one inhaler canister, one injection, or a 30-
day or less supply of an oral medication. For example, two inhaler canisters of 
the same medication dispensed on the same day count as two medication 
units and only one dispensing event.  
Use the package size and units columns in the NDC list to determine the 
number of canisters or injections. Divide the dispensed amount by the package 
size to determine the number of canisters or injections dispensed. For 
example, if the package size for an inhaled medication is 10 g and pharmacy 
data indicates the dispensed amount is  
30 g, this indicates 3 inhaler canisters were dispensed. 
Eligible Population  
Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 
20: Members in Hospice. 
Product lines Commercial, Medicaid, Medicare (report each product line separately). 
Ages For commercial, ages 5-85 as of December 31 of the measurement year. Report the 
following age stratifications and total rate: 
• 5–11 years. 
• 12–18 years. 
• 19–50 years. 
• 51–64 years. 
• 65–85 years. 
• Total. 
For Medicaid, ages 5–64 as of December 31 of the measurement year. Report the 
following age stratifications and total rate: 
• 5–11 years. 
• 12–18 years. 
• 19–50 years. 
• 51–64 years. 
• Total. 
For Medicare, ages 18–85 as of December 31 of the measurement year. Report the 
following age stratifications and total rate: 
• 18-50 years. 
• 51–64 years. 
• 65–85 years. 
• Total. 
The total is the sum of the age stratifications for each product line. 
Continuous 
enrollment 
The measurement year and the year prior to the measurement year. 
Allowable gap No more than one gap in enrollment of up to 45 days during each year of continuous 
enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom 
enrollment is verified monthly, the member may not have more than a 1-month gap in 
coverage during each year of continuous enrollment year. 
Anchor date December 31 of the measurement year. 




diagnosis Follow the steps below to identify the eligible population. 
Step 1 Identify members as having persistent asthma who met at least one of the following 
criteria during both the measurement year and the year prior to the measurement year. 
Criteria need not be the same across both years. 
• At least one ED visit (ED Value Set), with a principal diagnosis of asthma 
(Asthma Value Set). 
• At least one acute inpatient encounter (Acute Inpatient Value Set), with a 
principal diagnosis of asthma (Asthma Value Set). 
• At least four outpatient visits (Outpatient Value Set) or observation visits 
(Observation Value Set), on different dates of service, with any diagnosis of 
asthma (Asthma Value Set) and at least two asthma medication dispensing 
events (Table MMA-A). Visit type need not be the same for the four visits. 
• At least four asthma medication dispensing events (Table MMA-A). 
Step 2 A member identified as having persistent asthma because of at least four asthma 
medication dispensing events, where leukotriene modifiers or antibody inhibitors were 
the sole asthma medication dispensed in that year, must also have at least one 
diagnosis of asthma (Asthma Value Set), in any setting, in the same year as the 
leukotriene modifier or antibody inhibitor (i.e., the measurement year or the year prior 




Exclude members who met any of the following criteria: 
• Members who had any diagnosis from any of the following value sets, any time 
during the member’s history through December 31 of the measurement year: 
– Emphysema Value Set. 
– Other Emphysema Value Set. 
– COPD Value Set. 
– Obstructive Chronic Bronchitis Value Set. 
– Chronic Respiratory Conditions Due to Fumes/Vapors Value Set. 
– Cystic Fibrosis Value Set. 
– Acute Respiratory Failure Value Set. 
• Members who had no asthma medications (controller or reliever) dispensed 






Denominator The eligible population. 
Numerator The number of members who have a medication ratio of 0.50 or greater during the 
measurement year. Follow the steps below to calculate the ratio. 
Step 1 For each member, count the units of controller medications (Table AMR-A) dispensed 
during the measurement year. Refer to the definition of Units of medications.  
Step 2 For each member, count the units of reliever medications (Table AMR-A) dispensed 
during the measurement year. Refer to the definition of Units of medications.  
Step 3 For each member, sum the units calculated in step 1 and step 2 to determine units of 
total asthma medications.  
Step 4 For each member, calculate the ratio of controller medications to total asthma 
medications using the following formula. 
Units of Controller Medications (step 1) 
Units of Total Asthma Medications (step 
3) 
 
Step 5 Sum the total number of members who have a ratio of 0.50 or greater in step 4.  
Table AMR-A: Asthma Controller and Reliever Medications 
ASTHMA CONTROLLER MEDICATIONS 
Description Prescriptions 
Antiasthmatic combinations • Dyphylline-guaifenesin • Guaifenesin-theophylline 
Antibody inhibitors • Omalizumab   
Inhaled steroid combinations • Budesonide-formoterol • Fluticasone-salmeterol • Mometasone-formoterol 




• Fluticasone CFC free 
• Mometasone  
 
Leukotriene modifiers • Montelukast • Zafirlukast • Zileuton 
Mast cell stabilizers • Cromolyn  
Methylxanthines • Aminophylline • Dyphylline • Theophylline 
ASTHMA RELIEVER MEDICATIONS 
Description Prescriptions 
Short-acting, inhaled beta-2 
agonists 
• Albuterol • Levalbuterol • Pirbuterol 
Note: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by 




Data Elements for Reporting  
Organizations that submit HEDIS data to NCQA must provide the following data elements. 
Table AMR-1/2/3: Data Elements for Asthma Medication Ratio 
Data Elements Administrative 
Measurement year  
Data collection methodology (Administrative)  
Eligible population  For each age stratification and total 
Number of required exclusions For each age stratification and total 
Numerator events by administrative data For each age stratification and total 
Numerator events by supplemental data For each age stratification and total 
Reported rate For each age stratification and total 
Lower 95% confidence interval For each age stratification and total 




Medication Management for People With Asthma (MMA) 
SUMMARY OF CHANGES TO HEDIS 2017 
• No changes to this measure. 
Description 
The mean of members 5–85 years of age during the measurement year who were identified as 
having persistent asthma and were dispensed appropriate medications that they remained on 
during the treatment period. Two rates are reported: 
1. The mean of members who remained on an asthma controller medication for at least 50% 
of their treatment period. 
2. The mean of members who remained on an asthma controller medication for at least 75% 
of their treatment period. 
Note: For Medicaid, report only members 5–64 years of age. For Medicare, report only members 
18–85 years of age. 
Definitions 
IPSD Index prescription start date. The earliest prescription dispensing date for any asthma 
controller medication during the measurement year. 
Treatment 
period 
The period of time beginning on the IPSD through the last day of the measurement year.  
PDC Proportion of days covered. The number of days that a member is covered by at least 







One prescription of an amount lasting 30 days or less. To calculate dispensing events  
for prescriptions longer than 30 days, divide the days supply by 30 and round down to 
convert. For example, a 100-day prescription is equal to three dispensing events  
(100/30 = 3.33, rounded down to 3). Allocate the dispensing events to the appropriate 
year based on the date when the prescription is filled. 
Multiple prescriptions for different medications dispensed on the same day count as 
separate dispensing events. If multiple prescriptions for the same medication are 
dispensed on the same day, sum the days supply and divide by 30. Use the Drug ID to 
determine if the prescriptions are the same or different. 
• Two prescriptions for different medications dispensed on the same day, each with 
a 60-day supply, equals four dispensing events (two prescriptions with two 
dispensing events each). 
• Two prescriptions for different medications dispensed on the same day, each with 
a 15-day supply, equals two dispensing events (two prescriptions with one 
dispensing event each). 
• Two prescriptions for the same medication dispensed on the same day, each with 
a 15-day supply, equals one dispensing event (sum the days supply for a total of 
30 days). 
• Two prescriptions for the same medication dispensed on the same day, each with 





dispensing event  
When identifying the eligible population, use the definition below to count inhaler 
dispensing events. 
All inhalers (i.e., canisters) of the same medication dispensed on the same day 
count as one dispensing event. Medications with different Drug IDs dispensed on the 
same day are counted as different dispensing events. For example, if a member 
received three canisters of Medication A and two canisters of Medication B on the 
same date, it would count as two dispensing events. 
Allocate the dispensing events to the appropriate year based on the date when the 
prescription was filled. 
Use the Drug ID field in the NDC list to determine if the medications are the same or 
different. 
Injection 
dispensing event  
Each injection counts as one dispensing event. Multiple dispensed injections of the 
same or different medications count as separate dispensing events. For example, if 
a member received two injections of Medication A and one injection of Medication B 
on the same date, it would count as three dispensing events.  
Allocate the dispensing events to the appropriate year based on the date when the 
prescription was filled. 
Calculating 
number of days 
covered for the 
numerator  
If multiple prescriptions for different medications are dispensed on the same  
day, calculate number of days covered by a controller medication using the 
prescriptions with the longest days supply. For multiple different prescriptions 
dispensed on different days with overlapping days supply, count each day within the 
treatment period only once toward the numerator.  
If multiple prescriptions for the same medication are dispensed on the same 
or different day, sum the days supply and use the total to calculate the number 
of days covered by a controller medication. For example, three controller 
prescriptions for the same medication are dispensed on the same day, each with a 
30-day supply, sum the days supply for a total of 90 days covered by a controller.  
Subtract any days supply that extends beyond December 31 of the measurement 
year. 
Use the drug ID provided by the NDC to determine if the prescriptions are the same 
or different. 
Eligible Population 
Note: Members in hospice are excluded from the eligible population. Refer to General Guideline 
20: Members in Hospice. 
Product lines Commercial, Medicaid, Medicare (report each product line separately). 
Ages For commercial, ages 5-85 as of December 31 of the measurement year. Report the 
following age stratifications and total rate: 
• 5–11 years. 
• 12–18 years. 
• 19–50 years. 
• 51–64 years. 







For Medicaid, ages 5–64 as of December 31 of the measurement year. Report the 
following age stratifications and total rate: 
• 5–11 years. 
• 12–18 years. 
• 19–50 years. 
• 51–64 years. 
• Total. 
For Medicare, ages 18–85 as of December 31 of the measurement year. Report the 
following age stratifications and total rate: 
• 18-50 years. 
• 51–64 years. 
• 65–85 years. 
• Total. 
The total is the sum of the age stratifications for each product line. 
Continuous 
enrollment 
The measurement year and the year prior to the measurement year. 
Allowable gap No more than one gap in enrollment of up to 45 days during each year of continuous 
enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom 
enrollment is verified monthly, the member may not have more than a 1-month gap 
in coverage during each year of continuous enrollment year. 
Anchor date December 31 of the measurement year. 
Benefits Medical. Pharmacy during the measurement year. 
Event/diagnosis Follow the steps below to identify the eligible population for the measure. 
Step 1 Identify members as having persistent asthma who met at least one of the following 
criteria during both the measurement year and the year prior to the measurement 
year. Criteria need not be the same across both years. 
• At least one ED visit (ED Value Set), with a principal diagnosis of asthma 
(Asthma Value Set). 
• At least one acute inpatient encounter (Acute Inpatient Value Set), with a 
principal diagnosis of asthma (Asthma Value Set). 
• At least four outpatient visits (Outpatient Value Set) or observation visits 
(Observation Value Set) on different dates of service, with any diagnosis of 
asthma (Asthma Value Set) and at least two asthma medication dispensing 
events (Table MMA-A). Visit type need not be the same for the four visits. 





Table MMA-A: Asthma Medications 
Description  Prescriptions 
Antiasthmatic combinations • Dyphylline-guaifenesin • Guaifenesin-theophylline  
Antibody inhibitor • Omalizumab   
Inhaled steroid combinations • Budesonide-formoterol • Fluticasone-salmeterol • Mometasone-formoterol 




• Fluticasone CFC free 
• Mometasone 
Leukotriene modifiers • Montelukast • Zafirlukast • Zileuton 
Mast cell stabilizers • Cromolyn  
Methylxanthines • Aminophylline • Dyphylline • Theophylline 
Short-acting, inhaled beta-2 
agonists 
• Albuterol • Levalbuterol • Pirbuterol 
Note: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by 
November 1, 2016.  
Step 2 A member identified as having persistent asthma because of at least four asthma 
medication dispensing events, where leukotriene modifiers or antibody inhibitors were the 
sole asthma medication dispensed in that year, must also have at least one diagnosis of 
asthma (Asthma Value Set), in any setting, in the same year as the leukotriene modifier or 




Exclude members who met any of the following criteria: 
• Members who had any diagnosis from any of the following value sets, any time 
during the member’s history through December 31 of the measurement year: 
– Emphysema Value Set. 
– Other Emphysema Value Set. 
– COPD Value Set. 
– Obstructive Chronic Bronchitis Value Set. 
– Chronic Respiratory Conditions Due to Fumes/Vapors Value Set. 
– Cystic Fibrosis Value Set. 
– Acute Respiratory Failure Value Set. 
• Members who had no asthma controller medications (Table MMA-B) dispensed 
during the measurement year.  
Table MMA-B: Asthma Controller Medications 
Description Prescriptions 
Antiasthmatic combinations • Dyphylline-guaifenesin • Guaifenesin-theophylline  
Antibody inhibitor • Omalizumab   
Inhaled steroid combinations • Budesonide-formoterol • Fluticasone-salmeterol • Mometasone-formoterol 




• Fluticasone CFC free 
• Mometasone 
Leukotriene modifiers • Montelukast • Zafirlukast • Zileuton 
Mast cell stabilizers • Cromolyn  
Methylxanthines • Aminophylline • Dyphylline • Theophylline 
Note: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by 








The number of members who achieved a PDC of at least 50% for their asthma 
controller medications (Table MMA-B) during the measurement year.  
Medication 
Compliance 75% 
The number of members who achieved a PDC of at least 75% for their asthma 
controller medications (Table MMA-B) during the measurement year. Follow the steps 
below to identify numerator compliance. 
Step 1 Identify the IPSD. The IPSD is the earliest dispensing event for any asthma controller 
medication (Table MMA-B) during the measurement year. 
Step 2 To determine the treatment period, calculate the number of days beginning on the IPSD 
through the end of the measurement year.  
Step 3 Count the days covered by at least one prescription for an asthma controller 
medication (Table MMA-B) during the treatment period. To ensure that a days 
supply that extends beyond the measurement year is not counted, subtract any 
days supply that extends beyond December 31 of the measurement year. 
Step 4 Calculate the member’s PDC using the following equation. Round (using the .5 rule) to 
two decimal places. 
Total Days Covered by a Controller Medication in the Treatment Period (step 3) 
Total Days in Treatment Period (step 2) 
Medication 
Compliance 50% 
Sum the number of members whose PDC is ≥50% for their treatment period. 
Medication 
Compliance 75% 
Sum the number of members whose PDC is ≥75% for their treatment period. 
Data Elements for Reporting  
Organizations that submit HEDIS data to NCQA must provide the following data elements. 
Table MMA-1/2/3: Data Elements for Medication Management for People With 
Asthma 
Data Elements Administrative 
Measurement year  
Data collection methodology (Administrative)  
Eligible population Each rate, for each age stratification and total 
Number of required exclusions Each rate, for each age stratification and total 
Numerator events by administrative data Each rate, for each age stratification and total 
Numerator events by supplemental data Each rate, for each age stratification and total 
Reported rate Each rate, for each age stratification and total 
Lower 95% confidence interval Each rate, for each age stratification and total 







(Asthma Quick Care Reference, 2012) 
